Lifecare signs EU Declaration of Conformity for implant electronics

23 Feb 2026 07:00 CET

Bergen, Norway, 23 February 2026 -- Lifecare ASA (LIFE), a MedTech company
developing next-generation implantable Continuous Glucose Monitoring (CGM)
technology, today announces that it has signed the EU Declaration of
Conformity for the electronics used in its implant system.

The Declaration of Conformity confirms that the electronics module complies
with the applicable requirements under relevant European directives, including
electromagnetic compatibility (EMC) and radio equipment standards, based on
completed compliance testing and finalized technical documentation.

The Declaration has been issued following receipt and review of the final
accredited laboratory test reports for electromagnetic compatibility and radio
performance. The technical file supporting the Declaration has been completed
and archived in accordance with regulatory requirements.

The signed Declaration of Conformity applies to the electronics configuration
used in:

* The reproducible implant manufacturing batch.
* The implants currently deployed in the ongoing longevity study
(LFC-SEN-002).
* The planned First-in-Human study (pending approval).
* The first commercial veterinary product version.

"This represents the formal legal step required to complete the CE marking
process for the electronics module. The Declaration of Conformity confirms
that our finalized production-level electronics meet applicable European
regulatory requirements," says Joacim Holter, CEO of Lifecare ASA.

With the Declaration of Conformity now signed, Lifecare will proceed to
confirm CE marking status of the veterinary product configuration under
applicable EU directives.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

666426_Lifecare signs EU Declaration of Conformity for implant electronics.pdf